In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Thousands taking Mounjaro privately are inundating GP surgeries - clogging phone lines, exacerbating the 8am scramble for ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Novo Nordisk's new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop the ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...